Article Text

Download PDFPDF
The Glasgow Prognostic Score Determined During Concurrent Chemoradiotherapy Is an Independent Predictor of Survival for Cervical Cancer
  1. Takeshi Nishida, MD*,
  2. Keiichiro Nakamura, MD, PhD*,
  3. Junko Haraga, MD*,
  4. Chikako Ogawa, MD, PhD*,
  5. Tomoyuki Kusumoto, MD, PhD*,
  6. Noriko Seki, MD, PhD*,
  7. Hisashi Masuyama, MD, PhD*,
  8. Norihisa Katayama, MD, PhD,
  9. Susumu Kanazawa, MD, PhD and
  10. Yuji Hiramatsu, MD, PhD*
  1. *Departments of Obstetrics and Gynecology and
  2. Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  1. Address correspondence and reprint requests to Keiichiro Nakamura, MD, PhD, Department of Obstetrics and Gynecology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-tyo, Kita-ku, Okayama 700-8558, Japan. E-mail: k-nakamu{at}


Objective The Glasgow prognostic score (GPS) determined at pretreatment is important in the prediction of prognosis in various cancers. We investigated if the GPS used both at pretreatment and during concurrent chemoradiotherapy (CCRT) could predict the prognosis of patients with cervical cancer.

Methods We collected GPS and clinicopathological data from the medical records of 91 patients who underwent CCRT for cervical cancer; their GPSs at pretreatment and during CCRT were retrospectively analyzed for correlations with recurrence and survival. Statistical analyses were performed using the Mann-Whitney U test. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox’s proportional hazard regression was used for univariate and multivariate analyses.

Results The median follow-up for all patients who were alive at the time of last follow-up was 38.0 months (range, 1–108 months). The DFS and OS rates of patients with a high GPS during CCRT (GPS 1 + 2; 55 patients; 60.4%) were significantly shorter than those for patients with a low GPS (GPS 0; 36 patients; 39.6%) (DFS, P < 0.001; OS, P < 0.001). Furthermore, multivariate analyses showed that high GPS during CCRT was an independent prognostic factor of survival for OS (P = 0.008).

Conclusions During CCRT, a high GPS was revealed to be an important predictor of survival for cervical cancer.

  • Cervical cancer
  • During concurrent chemoradiotherapy
  • Glasgow prognostic score
  • Predictor for poor prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • This study was supported by the Japanese Ministry of Education, Culture, Sports, Science, and Technology (grants 25482595).

  • The authors declare no conflicts of interest.